The Biostatistics Core is a shared resource organized to meet the statistical needs of the USC Norris Comprehensive Cancer Center (NCCC) investigators. Statisticians in the Biostatistics Core collaborate with investigators in all the Cancer Center Programs - Molecular Genetics, Tumor Microenvironment, Epigenetics and Regulation, Developmental Therapeutics, Cancer Epidemiology, Cancer Control Research, Genitourinary Cancers, Gastrointestinal Cancers, Women's Cancers, and Leukemia and Lymphoma. The specific objectives of the Biostatistics Core are: 1. To provide statistical support to investigators at the NCCC in the design, planning, conduct, analysis, and reporting of cancer research studies 2. To ensure, in collaboration with members of the Clinical Investigations Support Office (CISO), the Cancer Research Informatics Core (CRIC), that clinical trials approved by the Clinical Investigations Committee (CIC) are properly executed and provide high quality clinical and translational research data, and ensure, in collaboration with the Translational Pathology Core (TPC) and CRIC, that disease-based databases and associated tumor banks, which serve as a resource for translational research, are supported and maintained 3. To adapt and incorporate, or develop, innovations in statistical and clinical trials methodology into the design and analysis of cancer research studies. Members of the Biostatistics Core participate in conceptualization and development of Cancer Center research projects, analyses for publications, development or adaptation of statistical methods, oversight and coordination activities, and other unanticipated needs of the Cancer Center. Core competencies include experimental design and data analysis, database design and utilization, and bioinformatics and analysis of high-throughput data. In the current application we are requesting partial funding for five Ph.D. statisticians, three M.S. level statisticians, and one Ph.D. level bioinformatician.
The use of modern statistical methods, analytic techniques, data processing and database design is an essential requirement of successful cancer clinical and translational research. The Biostatistics Core of the NCCC plays the central role in assuring that this requirement is fulfilled in research conducted by members of the Cancer Center.
|Battaglin, Francesca; Naseem, Madiha; Puccini, Alberto et al. (2018) Molecular biomarkers in gastro-esophageal cancer: recent developments, current trends and future directions. Cancer Cell Int 18:99|
|Zhang, Junjie; Zhao, Jun; Xu, Simin et al. (2018) Species-Specific Deamidation of cGAS by Herpes Simplex Virus UL37 Protein Facilitates Viral Replication. Cell Host Microbe 24:234-248.e5|
|Eriguchi, Yoshihiro; Nakamura, Kiminori; Yokoi, Yuki et al. (2018) Essential role of IFN-? in T cell-associated intestinal inflammation. JCI Insight 3:|
|Cobo, Eduardo R; Holani, Ravi; Moreau, France et al. (2018) Entamoeba histolytica Alters ileal Paneth Cell Functions in Intact and Muc2 Mucin Deficiency. Infect Immun :|
|Suenaga, Mitsukuni; Schirripa, Marta; Cao, Shu et al. (2018) Gene Polymorphisms in the CCL5/CCR5 Pathway as a Genetic Biomarker for Outcome and Hand-Foot Skin Reaction in Metastatic Colorectal Cancer Patients Treated With Regorafenib. Clin Colorectal Cancer 17:e395-e414|
|Thomas, Nancy E; Edmiston, Sharon N; Orlow, Irene et al. (2018) Inherited Genetic Variants Associated with Melanoma BRAF/NRAS Subtypes. J Invest Dermatol 138:2398-2404|
|Rhie, Suhn Kyong; Yao, Lijun; Luo, Zhifei et al. (2018) ZFX acts as a transcriptional activator in multiple types of human tumors by binding downstream of transcription start sites at the majority of CpG island promoters. Genome Res :|
|Pinto, Navin; DuBois, Steven G; Marachelian, Araz et al. (2018) Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial. Pediatr Blood Cancer 65:e27023|
|Hanna, Diana L; Loupakis, Fotios; Yang, Dongyun et al. (2018) Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study. Clin Colorectal Cancer 17:e471-e488|
|Müller, Fabian; Cunningham, Tyler; Stookey, Stephanie et al. (2018) 5-Azacytidine prevents relapse and produces long-term complete remissions in leukemia xenografts treated with Moxetumomab pasudotox. Proc Natl Acad Sci U S A 115:E1867-E1875|
Showing the most recent 10 out of 842 publications